Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Merck TbkISX:MERK +1.06%84 Days Inventory is 161.00 as of Mar. 2026, which is 27% below its 10-year median of 220.32. GuruFocus rates ISX:MERK with a GF Score™ of 84/100 and a GF Value™ of Rp4,945.20 (Modestly Undervalued). Among 923 Drug Manufacturers companies, PT Merck Tbk ranks worse than 58.4% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). PT Merck Tbk's Average Total Inventories for the
three
months ended in Mar. 2026 was Rp298,981 Mil. PT Merck Tbk's Cost of Goods Sold for the
three
months ended in Mar. 2026 was Rp169,453 Mil.
Hence, PT Merck Tbk's Days Inventory for the
three
months ended in Mar. 2026 was 161.00.
The historical rank and industry rank for PT Merck Tbk's Days Inventory or its related term are showing as below:
ISX:MERK'
s Days Inventory Range Over the Past 10 Years
Min: 145.35 Med: 220.32 Max: 279.07
Current: 184.66
During the past 13 years, PT Merck Tbk's highest Days Inventory was 279.07. The lowest was 145.35. And the median was 220.32.
ISX:MERK's Days Inventory is ranked worse than 58.4% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.38
vs ISX:MERK: 184.66
PT Merck Tbk's Days Inventory
declined
from Mar. 2025 (227.51) to Mar. 2026 (161.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
PT Merck Tbk's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.57.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
PT Merck Tbk's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.06.
PT Merck Tbk (ISX:MERK) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
PT Merck Tbk's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
PT Merck Tbk's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
PT Merck Tbk Days Inventory Related Terms
PT Merck Tbk Days Inventory Historical Data
* Premium members only.
The historical data trend for PT Merck Tbk's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:MERK vs ZTS, UTHR, VTRS: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Merck Tbk's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Merck Tbk Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Merck Tbk's Days Inventory distribution charts can be found below:
* The bar in red indicates where PT Merck Tbk's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Merck Tbk (ISX:MERK) has a Days Inventory of 161.00 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on PT Merck Tbk and its competitors. This is 27% below median its historical median of 220.32. Over the past decade, PT Merck Tbk's Days Inventory has ranged from 145.35 to 279.07. According to the industry distribution chart, PT Merck Tbk ranks #539 out of 923 companies in the Drug Manufacturers industry, placing it in the top 58.4%.
Is PT Merck Tbk's Days Inventory too high?
PT Merck Tbk's current Days Inventory of 161.00 is 27% below median its 10-year median of 220.32. Over the past 10 years, this metric has ranged from a low of 145.35 to a high of 279.07. The Drug Manufacturers industry median Days Inventory is 164.38. PT Merck Tbk's value of 161.00 is 2.1% below this industry median. Based on the distribution chart, PT Merck Tbk ranks #539 out of 923 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, PT Merck Tbk has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Merck Tbk's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Merck Tbk ranks #539 out of 923 companies for Days Inventory. This places PT Merck Tbk in the lower half of its industry. The industry median Days Inventory is 164.38. PT Merck Tbk's value of 161.00 is 2.1% below this benchmark. Historically, PT Merck Tbk's own Days Inventory has ranged from 145.35 to 279.07 over the past decade. While the company's 10-year median is 220.32 vs. the industry median of 164.38, PT Merck Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.38, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Merck Tbk's current Days Inventory of 161.00 is 2.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on PT Merck Tbk and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Merck Tbk's current Days Inventory is 161.00, which is 27% below median its own 10-year median of 220.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Merck Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Merck Tbk (ISX:MERK) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp4,945.20, compared to a current price of Rp3,800.00 — trading 23.2% below its estimated fair value. The current Days Inventory is 161.00, which is 27% below median its 10-year median of 220.32 and 2.1% below the Drug Manufacturers industry median of 164.38. PT Merck Tbk's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For PT Merck Tbk (ISX:MERK), the current Days Inventory is 161.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Merck Tbk (ISX:MERK) Overvalued in 2026?
Based on GuruFocus' analysis, PT Merck Tbk stock appears to be undervalued.
The current stock price of Rp3,800.00 is trading 23.2% below its estimated GF Value™ of Rp4,945.20.
GuruFocus considers PT Merck Tbk to be Modestly Undervalued.
Key valuation signals for ISX:MERK:
Days Inventory: 161.00 (27% below median its 10-year median of 220.32)
GF Value™: Rp4,945.20 vs. price of Rp3,800.00 (23.2% below fair value)
Industry Position: 2.1% below the Drug Manufacturers median (#539 of 923)
No single metric tells the full story. See the ISX:MERK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia. The company operates in three segments: Biopharma, Consumer Health, and Others. The company offers pharmaceutical and biological prescription medicines for colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, as well as thyroid disorders such as hypothyroidism.
84GF Score
Get the complete analysis for ISX:MERK
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:MERK has been successfully added to your 
